Driving novel endpoints and study designs in amyotrophic lateral sclerosis: closer examination of the ALSFRS-R subdomains and a new definition of fast and slow progressors
Ellis, R.; Nowell, W. B.; Patel, N.; Wipperman, M. F.; Lyu, J.; Mishra, S.; Scotina, A.; Tu, D.; Wagner, J. A.; Levy, O.
Show abstract
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease that leads to significant morbidity and mortality, but with substantial variability in the rate of progression [1,2]. A common primary outcome measure used in ALS clinical studies is the ALSFRS-R. Change in this measure may also be used to stratify fast and slow progressors, typically with the assumption of linear decline. Reported limitations of the ALSFRS-R and the assumption of linear slope may hinder novel therapy development. Here we use two distinct populations from a clinical trial database (PRO-ACT) and a natural history registry (ALS TDI) to show that ALSFRS-R fine and gross motor subdomains are more sensitive to disease progression than total score and bulbar and respiratory subdomain scores. We also present a novel non-linear method for defining fast and slow progressors. Together these results may improve demonstration of outcomes in ALS interventional studies using the ALSFRS-R.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A low molecular weight dextran sulphate, ILB(R), for the treatment of amyotrophic lateral sclerosis (ALS): an open-label, single-arm, single-centre, phase II trial 93%
- Network diffusion model predicts neurodegeneration in limb-onset amyotrophic lateral sclerosis 91%
- Clinical Trials for Wolfram Syndrome Neurodegeneration: Novel Design, Endpoints, and Analysis Models 91%
Similar papers in this journal
- Improving prediction models of amyotrophic lateral sclerosis (ALS) using polygenic, pre-existing conditions, and survey-based risk scores in the UK Biobank 93%
- Assessment of the Reliability, Responsiveness, and Meaningfulness of the Scale for the Assessment and Rating of Ataxia (SARA) for Lysosomal Storage Disorders 91%
- Acetyl-L-leucine for Niemann-Pick type C – a multi-national, rater-blinded phase II trial 90%
Similar papers in this journal
- The oligogenic structure of amyotrophic lateral sclerosis has genetic testing, counselling, and therapeutic implications 93%
- Metal mixtures associate with higher amyotrophic lateral sclerosis risk and mortality independent of genetic risk and correlate to self-reported exposures: a case-control study 90%
- Predicting loss of independence and mortality in frontotemporal lobar degeneration syndromes 89%
Similar papers in this journal
- Validation of Serum Neurofilaments as Prognostic & Potential Pharmacodynamic Biomarkers for ALS 92%
- Novel associations of BST1 and LAMP3 with rapid eye movement sleep behavior disorder 88%
- Serum NfL in spinocerebellar ataxia type 1 is increased already at the preataxic stage, correlating with proximity to clinical onset 87%
Similar papers in this journal
- Reliable Monitoring of Respiratory Function with Home Spirometry in People Living with Amyotrophic Lateral Sclerosis 91%
- Metabolic and muscle-derived serum biomarkers define CHCHD10-linked late-onset spinal muscular atrophy 90%
- A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease (PASADENA): rationale, design and baseline data 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.